[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 22, 1980

Clinical Experience With a Human Diploid Cell Rabies Vaccine

Author Affiliations

From the Viral Diseases Division, Bureau of Epidemiology, Center for Disease Control, Atlanta (Drs Anderson and Winkler); Texas Department of Health, Austin (Dr Hafkin); National Institute for Occupational Safety and Health, Center for Disease Control, Cincinnati (Dr Keenlyside); Division of Internal Medicine, Department of Medicine, Georgetown University Medical Center, Washington, DC (Dr D'Angelo); and Wyeth Laboratories Division, Radnor, Pa (Dr Deitch). Drs Hafkin, Keenlyside, and D'Angelo were formerly with the Viral Diseases Division, Bureau of Epidemiology, Center for Disease Control, Atlanta.

JAMA. 1980;244(8):781-784. doi:10.1001/jama.1980.03310080015015
Abstract

Between January 1975 and December 1977 the Center for Disease Control treated 255 persons with the human diploid cell strain rabies vaccine who did not have development of an antibody titer to duck embryo vaccine (DEV) or who were at risk for having a serious reaction to DEV. Two hundred eighteen persons were treated postexposure, and 37 persons were treated preexposure. The antibody response to the vaccine was excellent, and the reaction rates were low. No person treated has had development of rabies. This study corroborates other studies that suggest that the human diploid cell strain rabies vaccines are safe and induce excellent antibody titers to rabies.

(JAMA 244:781-784, 1980)

×